About Uni-bio science group limited 联康生物科技集团有限公司
Uni-bio Science Group Limited: A Leading Chinese Biopharmaceutical and Healthcare Company
Uni-bio Science Group Limited (HKEX: 0690) is a prominent biopharmaceutical and healthcare company based in China. The company is primarily engaged in the research, development, production, and commercialization of biopharmaceutical products for the Chinese healthcare market.
With a strong focus on innovation and quality, Uni-bio Science Group has established itself as a leader in the Chinese biopharmaceutical industry. The company's mission is to improve people's health by providing safe, effective, and affordable medicines that meet the highest standards of quality.
Uni-bio Science Group's product portfolio includes a wide range of therapeutic areas such as oncology, immunology, cardiovascular diseases, infectious diseases, and metabolic disorders. The company has developed several innovative drugs that have been approved by regulatory authorities in China.
One of Uni-bio Science Group's flagship products is Yisaipu®, an innovative drug for treating non-small cell lung cancer (NSCLC). Yisaipu® has been approved by the National Medical Products Administration (NMPA) in China and has shown promising results in clinical trials.
In addition to its strong product pipeline, Uni-bio Science Group also has state-of-the-art manufacturing facilities that comply with international standards such as Good Manufacturing Practice (GMP). The company's manufacturing capabilities include fermentation technology for producing recombinant proteins and monoclonal antibodies.
Uni-bio Science Group also places great emphasis on research and development (R&D), investing heavily in this area to develop new drugs that address unmet medical needs. The company collaborates with leading academic institutions and research organizations to advance its R&D efforts.
Furthermore, Uni-bio Science Group has established strategic partnerships with global pharmaceutical companies to expand its product portfolio beyond China. These partnerships enable the company to leverage its expertise in drug development while accessing new markets and technologies.
Uni-bio Science Group's commitment to quality, innovation, and patient-centricity has earned it a strong reputation in the Chinese biopharmaceutical industry. The company's vision is to become a global leader in biopharmaceuticals by developing innovative drugs that improve people's health and well-being.
In conclusion, Uni-bio Science Group Limited is a leading Chinese biopharmaceutical and healthcare company that is committed to improving people's health through innovation, quality, and patient-centricity. With its strong product pipeline, state-of-the-art manufacturing facilities, and strategic partnerships with global pharmaceutical companies, Uni-bio Science Group is well-positioned for continued growth in the years ahead.